ECSP23041151A - Ácidos pirazolo piperidin carboxílicos sustituidos - Google Patents
Ácidos pirazolo piperidin carboxílicos sustituidosInfo
- Publication number
- ECSP23041151A ECSP23041151A ECSENADI202341151A ECDI202341151A ECSP23041151A EC SP23041151 A ECSP23041151 A EC SP23041151A EC SENADI202341151 A ECSENADI202341151 A EC SENADI202341151A EC DI202341151 A ECDI202341151 A EC DI202341151A EC SP23041151 A ECSP23041151 A EC SP23041151A
- Authority
- EC
- Ecuador
- Prior art keywords
- diseases
- carboxylic acids
- preparation
- hypertension
- pulmonary
- Prior art date
Links
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 title 1
- 150000001735 carboxylic acids Chemical class 0.000 title 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000008960 Diabetic foot Diseases 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 2
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 2
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 abstract 2
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 2
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 2
- 208000007056 sickle cell anemia Diseases 0.000 abstract 2
- CANSPPZTVXEOJH-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-b]pyridine-3-carboxylic acid Chemical class C1CCNC2=C1NN=C2C(=O)O CANSPPZTVXEOJH-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 201000006306 Cor pulmonale Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 abstract 1
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a ácidos pirazolo piperidin carboxílicos sustituidos, sus sales y a procesos para su preparación, y también a su uso para la preparación de medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular enfermedades cardiovasculares y cardíacas, preferiblemente insuficiencia cardíaca con fracción de eyección reducida y conservada (HFrEF, HFmrEF y HFpEF), hipertensión (HTN), enfermedades de arterias periféricas (PAD, PAOD), enfermedades cardiorrenales y renales, preferiblemente enfermedad renal crónica y diabética (CKD y DKD), enfermedades cardiopulmonares y pulmonares, preferiblemente hipertensión pulmonar (PH), y otras enfermedades, preferiblemente enfermedades neurodegenerativas y diferentes formas de demencias, enfermedades fibróticas, esclerosis sistémica (SSc), enfermedad de células falciformes (SCD), trastornos de cicatrización de heridas como la úlcera del pie diabético (DFU).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20213016.7A EP4011873A1 (en) | 2020-12-10 | 2020-12-10 | Substituted pyrazolo piperidine carboxylic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23041151A true ECSP23041151A (es) | 2023-07-31 |
Family
ID=73793021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202341151A ECSP23041151A (es) | 2020-12-10 | 2023-06-02 | Ácidos pirazolo piperidin carboxílicos sustituidos |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20220274958A1 (es) |
| EP (2) | EP4011873A1 (es) |
| JP (1) | JP7451700B2 (es) |
| KR (1) | KR20230118145A (es) |
| CN (1) | CN114981257B (es) |
| AR (1) | AR124196A1 (es) |
| AU (1) | AU2021393987A1 (es) |
| CA (1) | CA3204491A1 (es) |
| CL (1) | CL2023001633A1 (es) |
| CO (1) | CO2023007334A2 (es) |
| CR (1) | CR20230238A (es) |
| DO (1) | DOP2023000114A (es) |
| EC (1) | ECSP23041151A (es) |
| GE (1) | GEP20247635B (es) |
| IL (1) | IL303299A (es) |
| MX (1) | MX2023006904A (es) |
| PE (1) | PE20231502A1 (es) |
| TW (1) | TW202237588A (es) |
| WO (1) | WO2022122910A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4011873A1 (en) * | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| TW202412753A (zh) | 2022-06-09 | 2024-04-01 | 德商拜耳廠股份有限公司 | 用於治療女性心臟衰竭合併保留射出分率的可溶性鳥苷酸環化酶活化劑 |
| WO2024163561A1 (en) * | 2023-01-31 | 2024-08-08 | Invivosciences, Inc. | Systems and methods for treating heart failure with preserved ejection fraction |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) * | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| AU2008296974B2 (en) | 2007-09-06 | 2013-10-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| CA2791100C (en) | 2010-02-27 | 2018-01-30 | Bayer Intellectual Property Gmbh | Bisaryl-bonded aryltriazolones and use thereof |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| EA201390060A1 (ru) | 2010-07-09 | 2013-07-30 | Байер Интеллектуэль Проперти Гмбх | Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| WO2015095515A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
| MA40893B1 (fr) | 2014-11-03 | 2018-11-30 | Bayer Pharma AG | Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées |
| EP4011873A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| CN116829545A (zh) | 2020-12-10 | 2023-09-29 | 拜耳公司 | 取代的吡唑基哌啶羧酸 |
| EP4011874A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| MX2023006903A (es) | 2020-12-10 | 2023-06-26 | Bayer Ag | Acidos pirazol piperidin carboxilicos sustituidos. |
| AU2021398486A1 (en) * | 2020-12-10 | 2023-06-22 | Bayer Aktiengesellschaft | The use of sgc activators for the treatment of ophthalmologic diseases |
-
2020
- 2020-12-10 EP EP20213016.7A patent/EP4011873A1/en not_active Ceased
-
2021
- 2021-12-09 PE PE2023001810A patent/PE20231502A1/es unknown
- 2021-12-09 JP JP2022526369A patent/JP7451700B2/ja active Active
- 2021-12-09 CR CR20230238A patent/CR20230238A/es unknown
- 2021-12-09 TW TW110146018A patent/TW202237588A/zh unknown
- 2021-12-09 MX MX2023006904A patent/MX2023006904A/es unknown
- 2021-12-09 EP EP21820285.1A patent/EP4259615A1/en active Pending
- 2021-12-09 GE GEAP202116286A patent/GEP20247635B/en unknown
- 2021-12-09 KR KR1020237022819A patent/KR20230118145A/ko unknown
- 2021-12-09 WO PCT/EP2021/084980 patent/WO2022122910A1/en active Application Filing
- 2021-12-09 CA CA3204491A patent/CA3204491A1/en active Pending
- 2021-12-09 AU AU2021393987A patent/AU2021393987A1/en active Pending
- 2021-12-09 IL IL303299A patent/IL303299A/en unknown
- 2021-12-09 CN CN202180008063.XA patent/CN114981257B/zh active Active
- 2021-12-09 AR ARP210103423A patent/AR124196A1/es unknown
-
2022
- 2022-02-08 US US17/667,410 patent/US20220274958A1/en active Pending
-
2023
- 2023-04-13 US US18/134,378 patent/US20230265072A1/en active Granted
- 2023-06-02 CO CONC2023/0007334A patent/CO2023007334A2/es unknown
- 2023-06-02 EC ECSENADI202341151A patent/ECSP23041151A/es unknown
- 2023-06-06 CL CL2023001633A patent/CL2023001633A1/es unknown
- 2023-06-07 DO DO2023000114A patent/DOP2023000114A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GEP20247635B (en) | 2024-06-25 |
| AU2021393987A1 (en) | 2023-06-22 |
| CA3204491A1 (en) | 2022-06-16 |
| US20230265072A1 (en) | 2023-08-24 |
| EP4011873A1 (en) | 2022-06-15 |
| IL303299A (en) | 2023-07-01 |
| MX2023006904A (es) | 2023-06-26 |
| US20220274958A1 (en) | 2022-09-01 |
| KR20230118145A (ko) | 2023-08-10 |
| JP7451700B2 (ja) | 2024-03-18 |
| JP2023543646A (ja) | 2023-10-18 |
| CL2023001633A1 (es) | 2023-11-10 |
| DOP2023000114A (es) | 2023-07-09 |
| CN114981257B (zh) | 2024-07-05 |
| EP4259615A1 (en) | 2023-10-18 |
| CO2023007334A2 (es) | 2023-06-09 |
| WO2022122910A1 (en) | 2022-06-16 |
| PE20231502A1 (es) | 2023-09-26 |
| CN114981257A (zh) | 2022-08-30 |
| TW202237588A (zh) | 2022-10-01 |
| AR124196A1 (es) | 2023-02-22 |
| CR20230238A (es) | 2023-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23041151A (es) | Ácidos pirazolo piperidin carboxílicos sustituidos | |
| CL2023001632A1 (es) | Ácidos pirazol piperidin carboxílicos sustituidos | |
| Okafor et al. | Allopurinol as a therapeutic option in cardiovascular disease | |
| EA201491433A1 (ru) | Синтетические миметики апелина для лечения сердечной недостаточности | |
| WO2014188279A3 (en) | Apparatus for delivering devices for reducing left atrial pressure | |
| Macon et al. | Acute myocardial infarction | |
| Kraiem et al. | P4718 Follow up in heart failure center versus routine practice: which positive impact we can have? | |
| Mahmood | Serum potassium and calcium level in patients with post-myocardial infarction ventricular fibrillation | |
| Reddy | Assessment of ECG and echo findings among with chronic kidney disease patients | |
| Banerjee et al. | Comparison of Echocardiographic Patterns between Mild to Moderate and Severe CKD with type 4 Cardio renal Syndrome Patients | |
| Rusnanta et al. | Right-Sided Heart Failure Presentation in Severe Valvular Aortic Stenosis: How to Deal with Diuretic Use? | |
| Berad et al. | Study of Cardiovascular Manifestations in Patients with Thyroid dysfunction at Tertiary Care Center | |
| Raguindin et al. | FP20 The 7 mHz of Love: Assessment of Systolic Function using Bedside Ultrasound of Ten Patients with Chronic Kidney Disease Presenting with Pulmonary Congestion at the Emergency Department of Southern Philippines Medical Center | |
| Galiuto et al. | Functional Tricuspid Regurgitation Repair at the time of Left-Sided Valve Surgery. the Impact on the Cardiac Rehabilitation Program | |
| RU2004105673A (ru) | Способ оценки тяжести хронической сердечной недостаточности | |
| Aggarwal et al. | Management of a Case of Aortic Valve Replacement with Left Ventricle Clot Removal Developing Acute Kidney Injury in Postoperative Period | |
| Rajan et al. | 2nd World Heart Congress | |
| Lang et al. | Pulmonary Artery Endovascular Device to Improve Vascular Compliance in Pulmonary Hypertension | |
| Andor et al. | A factorial binary score for prognosis of acute decompensated heart failure | |
| Schmid et al. | Can goal-directed hemodynamic management improve renal outcome after major non-cardiac surgery?: 4AP3-2 | |
| Wasserstrum | Amiodarone/ibrutinib interaction | |
| Ghamloush et al. | D45 CRITICAL CARE: CIRCULATORY HEMODYMANICS, SHOCK, CARDIOVASCULAR DISEASE, AND FLUID MANAGEMENT: Anticoagulation May Increase The Risk Of Acute Respiratory Failure In Patients With Acute Cardiogenic Pulmonary Edema | |
| WO2018051294A3 (en) | Non—saponifiable compounds of natural lipids for use in the treatment of cardiac pathologies | |
| Foroughi et al. | Cardiovascular Complications and Management After Cardiac Surgery | |
| Kaushik et al. | EPICARDIAL ADIPOSE TISSUE THICKNESS AS ASSESSED BY ECHOCARDIOGRAPHY & DIASTOLIC LEFT VENTRICULAR FUNCTION |